 BioMarin Pharmaceutical Inc NASDAQ: BMRN announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A. Annualized Bleeding Rate ABR was significantly reduced by 4.1 treated bleeds per year in the pre-specified primary analysis in participants from a prior non-interventional study. 